Predictable signs of benign course of polypoidal choroidal vasculopathy: based upon the long-term observation of non-treated eyes

被引:12
|
作者
Okubo, Akiko [1 ]
Arimura, Noboru [1 ]
Abematsu, Noriko [1 ]
Sakamoto, Taiji [1 ]
机构
[1] Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan
关键词
benign; clinical course; polypoidal choroidal vasculopathy; predictable sign; visual prognosis; INTRAVITREAL BEVACIZUMAB AVASTIN; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
D O I
10.1111/j.1755-3768.2009.01850.x
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To find predictable signs of benign polypoidal choroidal vasculopathy (PCV). Methods: Medical records of 13 eyes from 12 patients who were followed up for 5 years or longer without treatment among 258 consecutive patients with PCV were reviewed retrospectively. The main outcomes measured were best corrected visual acuity (BCVA) and fundus findings during the follow-up period. Results: The average age at presentation was 68 years, and the average follow-up period after diagnosis was 80 months (range, 62-119 months). The initial mean logarithmic value of the minimal angle of resolution (logMAR) BCVA was 0.28 +/- 0.26, and the final mean logMAR BCVA was 0.62 +/- 0.72. The difference in the logMAR BCVA values between the two points was not statistically significant (p > 0.05). The trend of change from baseline at 2-year follow-up was consistent with those at 5-year follow-up in nine eyes. Fundus findings at the initial examination were classified into two patterns: (i) reddish-orange nodules and detachment of the retinal pigment epithelium with/without detachment of the neurosensory retina (nine eyes); (ii) reddish-orange nodules alone, or nodules and small subretinal haemorrhage (four eyes). In the eyes with the first pattern, clinical course and visual prognosis were variable. An absence of hard exudates could be a sign to maintain a benign clinical course or stable vision with this pattern. The eyes with the second pattern took a benign clinical course with stable vision. Conclusions: There is certainly a group of PCV eyes with a benign prognosis. Considering the huge cost and risk of current therapies, the initial ocular findings could be deciding factors that determine the necessity for further treatment.
引用
收藏
页码:e107 / e114
页数:8
相关论文
共 35 条
  • [1] Long-Term Prognosis of Patients with Polypoidal Choroidal Vasculopathy Treated with Photodynamic Therapy
    Sakaeda, Yukinori
    Kato, Aki
    Kuwayama, Soichiro
    Hirahara, Shuichiro
    Suzuki, Norihiro
    Ogura, Yuichiro
    Nakazawa, Yoko
    Yasukawa, Tsutomu
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (14)
  • [2] Long-term cults of photodynamic therapy of polypoidal choroidal vasculopathy
    Akaza, Eriko
    Mori, Ryusaburo
    Yuzawa, Mitsuko
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (05): : 717 - 722
  • [3] Long-Term Incidence and Growth of Chorioretinal Atrophy in Patients with Polypoidal Choroidal Vasculopathy
    Choi, Eun Young
    Park, Sung Eun
    Lee, Sung Chul
    Koh, Hyoung Jun
    Kim, Sung Soo
    Byeon, Suk Ho
    Kim, Min
    Lee, Christopher Seungkyu
    OPHTHALMOLOGICA, 2020, 243 (02) : 136 - 144
  • [4] Long-term outcomes of focal laser photocoagulation for the treatment of polypoidal choroidal vasculopathy
    Choe, Sooyeon
    Kang, Hyun Goo
    Park, Kyu Hyung
    Lee, Christopher Seungkyu
    Woo, Se Joon
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2021, 14 (09) : 1402 - 1407
  • [5] Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapy
    Kikushima, Wataru
    Sakurada, Yoichi
    Yoneyama, Seigo
    Sugiyama, Atsushi
    Matsubara, Mio
    Fukuda, Yoshiko
    Kashiwagi, Kenji
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2021, 35
  • [6] Long-term observation of vitrectomy without subretinal hemorrhage management for massive vitreous hemorrhage secondary to polypoidal choroidal vasculopathy
    Li, Zhi-Xi
    Hu, Yi-Jun
    Atik, Alp
    Lu, Lin
    Hu, Jie
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2019, 12 (12) : 1859 - 1864
  • [7] Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy
    Inoue, M.
    Arakawa, A.
    Yamane, S.
    Kadonosono, K.
    EYE, 2013, 27 (09) : 1013 - 1020
  • [8] Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy
    Takayama, Kei
    Kaneko, Hiroki
    Kataoka, Keiko
    Ueno, Shinji
    Chang-Hua, Piao
    Ito, Yasuki
    Terasaki, Hiroko
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (03) : 449 - 455
  • [9] Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy
    Kei Takayama
    Hiroki Kaneko
    Keiko Kataoka
    Shinji Ueno
    Piao Chang-Hua
    Yasuki Ito
    Hiroko Terasaki
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 449 - 455
  • [10] Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin
    Sayanagi, Kaori
    Gomi, Fumi
    Sawa, Miki
    Ohji, Masahito
    Tano, Yasuo
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2007, 245 (10) : 1569 - 1571